Elke Lipka, PhD and Andrew Hertig, TSRL

TSRL


Topic: The TSRL Preclinical Accelerator: Driving Value from Lead to Clinic

Date: Friday, November 11 
Time: 9  to 10 a.m.
Place: B448 Life Science Bldg 
 
Therapeutic Systems Research Laboratories (TSRL), Inc., is a privately-owned pharmaceutical specialty company based in Ann Arbor, Michigan. Through our preclinical accelerator model, we partner with academic investigators to advance their promising lead-stage therapeutic concepts to clinical-readiness by providing scientific and business expertise and access to capital. Our core competencies include pharmacokinetics, formulation development, toxicology, data and project management, regulatory strategy, grant-writing, and business development. Our portfolio programs have received over $15 million in grant support over the past ten years and generated ~$20 million in revenues from out-licenses and acquisitions. A strategic priority for us continues to be the development of new anti-infective therapeutics for treating severe and multi-drug resistant infectious diseases, with an emphasis on viral and bacterial infections.